🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

XBIO XBIO

Company Profile ↓
$4.27
+37.65% 1Y
Mkt Cap$9.79M
P/E-2.70
P/B0.98
52W High$10.36
52W Low$2.02
Book Value$3.22
EPS (TTM)$-1.58

Company Overview

XBIO (XBIO) is a publicly traded company listed on with a market capitalization of $9.79M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 26.3% CAGR over the past five years.

Recent Developments

  • Dec 2025 Revenue of $2.98M (+19.0% YoY); net profit $-2.68M.
  • Trailing 12 Months Year-on-year growth — revenue +19.0%.
  • 5-Year Trend Long-term compounding — revenue CAGR 26.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:26.34%
1 Year:19.04%

Stock Price Performance

1 Year:+37.65%
6 Months:+26.33%
3 Months:+31.79%
1 Month:+30.18%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 27% of range
$2.02 $10.36
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)61.79 · Neutral
Price Performance
1M+30.18%
3M+31.79%
6M+26.33%
1Y+37.65%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 26.3% over 5 years.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading 58.8% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-2.70
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$3.22
Price to Book
0.98
P/S
2.44
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
26.34%
Profit 5Y
-
Revenue (YoY)
19.04%
Earnings (YoY)
-

Profitability & Returns

ROCE
-38.33%
ROE
-36.25%
ROA
-32.05%
Profit Margin
-90.07%
Op Margin
-95.23%
Gross Margin
0.00%
EPS (Latest Qtr)
$-0.20
EPS (TTM)
$-1.58

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
8.32
Debt
-
Total Assets
$7.91M
Current Assets
$7.60M
Working Capital
$7.08M

Ownership

Promoter Holding
15.42%
Chg in Prom Hold
-
FII / Inst Holding
6.49%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$9.79M
Total Revenue (TTM)
$2.98M
EBITDA
$-2.83M
Free Cash Flow
$-2.29M
Operating Cash Flow
$-2.29M
Shares Outstanding
2.29M
Gross Margin
0.00%
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2013Nov 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -2.17K0--0----0--85.00K--000056.75K112.93K115.93K191.22K287.60K349.27K388.99K416.71K414.25K605.84K651.00K611.17K510.82K726.40K614.24K593.26K589.90K1.03M766.30K806.92K
Cost of Revenue ----------------------------------------
Gross Profit --0--0----------------------------------
Operating Expenses -----------------------------------1.54M1.31M1.57M1.39M1.31M
Operating Income -2.53M-76.77K-2.96M-2.64M-3.11M-1.97M-1.36M-3.80M-1.85M-43.26M-2.25M-2.86M-2.90M-2.24M-1.83M-1.99M-1.81M-1.33M-1.38M-8.95M-1.23M-982.46K-10.50M-1.37M-1.13M-1.38M-1.62M-2.69M-847.79K-915.17K-1.20M-1.15M-1.27M-1.34M-499.47K-942.41K-724.41K-544.73K-623.03K-502.12K
EBITDA ------------------------------------942.41K-724.41K-544.73K-623.03K-502.12K
Interest Expense ----------------------------------------
Pretax Income ------------------------------------903.14K-688.70K-509.94K-579.08K-456.38K
Tax Provision ----------------------------------------
Net Income --82.46K-4.06M-2.76M-3.18M-2.43M-1.13M-5.32M-3.57M-47.77M-2.47M-2.87M-2.92M-2.26M-1.82M-2.03M-1.81M-1.33M-1.38M-8.90M-1.18M-953.64K-7.56M-1.35M-1.11M-1.35M-1.59M-2.67M-804.02K-856.55K-1.05M-1.06M-1.20M-1.27M-436.67K-903.14K-688.70K-509.94K-579.08K-456.38K
Diluted EPS -------------------------0.13-0.13-0.12-1.90-0.56-0.56-0.69-0.69-0.78-0.83-0.28-0.59-0.45-0.33--0.20
R&D Expense 1.04M-564.89K1.03M1.91M1.04M555.74K816.32K429.28K2.21M891.83K1.22M873.84K884.80K706.27K927.07K735.88K463.78K487.52K3.52M359.65K307.90K573.06K629.73K524.55K780.15K1.10M2.08M398.80K595.28K903.24K1.02M944.32K933.77K367.99K879.03K656.56K756.48K-661.44K

Profit & Loss (Annual)

Figures in USD.

Metric Aug 2012Dec 2012Aug 2013Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 112.79K293.60K96.90K1.00M003.00M7.58M017.07K436.94K-1.71M2.54M2.50M2.98M
Cost of Revenue ----------------
Gross Profit -248.76K-1.00M0-----------
Operating Expenses ------------8.42M7.06M6.70M5.81M
Operating Income -116.66K-6.34M-65.56K-8.61M-12.92M-9.82M-47.43M-3.57M-7.28M-12.89M-13.94M--6.72M-4.52M-4.20M-2.83M
EBITDA -------------6.69M-4.52M-4.20M-2.83M
Interest Expense ----------------
Pretax Income -------------6.55M-4.13M-3.96M-2.68M
Tax Provision -----------0----
Net Income -89.17K--89.17K-8.58M-14.31M-12.51M-54.21M-3.60M-7.30M-12.78M-10.89M--6.55M-4.13M-3.96M-2.68M
Diluted EPS -------------4.61-2.71-2.57-1.58
R&D Expense -1.94M-3.06M6.32M3.43M43.74M4.06M2.88M4.89M1.73M3.16M4.77M3.49M3.29M3.07M

Balance Sheet (Annual)

Figures in USD.

Metric Aug 2011Dec 2011Aug 2012Dec 2012Aug 2013Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets 222.50K-324.13K25.37M486.81K19.47M16.32M16.91M20.97M19.16M14.43M21.55M13.18M-14.72M10.61M6.90M8.36M
Current Assets --------------13.65M9.59M6.59M8.05M
Cash & Equivalents --------------13.10M8.98M6.17M7.88M
Inventory ------------------
Receivables ------------------
Total Liabilities 220.74K-417.04K4.59M668.89K6.85M5.84M10.30M4.80M4.86M4.52M4.33M963.97K-1.07M809.59K894.26K968.02K
Current Liabilities 7.92K-204.23K1.40M456.08K3.59M2.70M7.34M1.87M1.94M1.60M1.42M936.93K-1.07M809.59K894.26K968.02K
Long Term Debt 212.81K-212.81K-212.81K-------------
Total Debt ------------------
Total Equity 1.76K14.80M-92.91K20.78M-182.08K12.62M10.48M6.61M16.17M14.30M9.91M17.21M12.22M-13.65M9.80M6.01M7.40M
Shares Outstanding --------------1.52M1.54M1.54M2.29M

Cash Flows (Annual)

Figures in USD.

Metric Aug 2012Dec 2012Aug 2013Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -12.99K-6.26M280.61K-6.05M---8.79M1.49M-6.46M-6.40M-4.27M--4.65M-4.11M-2.82M-2.29M
Investing Cash Flow --92.59K-259.39K-144.63K---16.79K-9.26K22.50K2.00K00-500.00K0--
Financing Cash Flow 35.00K-303.35K-2.09K--12.72M01.48M16.13M5.43M11.45M0-04.00M
Capital Expenditure --130.08K-212.50K-78.63K-57.67K-1.66K-16.79K-9.26K-0----500.00K---
Free Cash Flow --6.39M68.11K-6.13M---8.80M1.48M-6.46M----5.15M-4.11M-2.82M-2.29M
Net Change in Cash -------------5.15M-4.11M-2.82M1.72M

Ratios (Annual)

Figures in %.

Metric Aug 2012Dec 2012Aug 2013Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -84.7%-100.0%------------
Operating Margin % -103.4%-2,160.8%-67.7%-861.3%---1,581.0%-47.1%--75,511.7%-3,189.8%--393.6%-177.8%-168.2%-95.2%
Net Margin % -79.1%--92.0%-857.9%---1,806.9%-47.4%--74,856.6%-2,493.1%--383.9%-162.8%-158.4%-90.1%
ROE % 96.0%-49.0%-68.0%-136.5%-189.3%-335.2%-25.1%-73.6%-74.2%-89.2%--48.0%-42.2%-65.9%-36.2%
ROCE % -97.3%-26.5%-213.3%-54.3%-94.9%-102.7%-248.2%-20.7%-56.7%-64.0%-113.8%--49.2%-46.1%-70.0%-38.3%

Shareholding Pattern

Insiders
15.42%
Institutions
6.49%
Public Float
7.67%

Top Institutional Holders

#Holder% HeldSharesValue
1 Renaissance Technologies, LLC 5.13% 117.44K $467.41K
2 Geode Capital Management, LLC 0.76% 17.42K $69.34K
3 Vanguard Capital Management LLC 0.55% 12.68K $50.47K
4 JTC Employer Solutions Trustee Ltd. 0.12% 2.70K $10.75K
5 SBI Securities Co., Ltd. 0.04% 1.00K $3.98K
6 Tower Research Capital LLC (TRC) 0.03% 696 $2.77K
7 Morgan Stanley 0.01% 150 $597
8 Darwin Wealth Management, LLC - 2 $7

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for XBIO

Yahoo Finance Wed, 16 Sep 2026

Xenetic Biosciences Announces All-Stock Merger with Santersus, Leaving Existing Shareholders with 15% Stake

The proposed transaction would create a Nasdaq-listed company focused on NET-targeting therapies, combining four clinical programs while transferring majority ownership to Santersus shareholders. Key Investor TakeawaysXenetic Biosciences (N…

Yahoo Finance Wed, 16 Sep 2026

Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition

Xenetic Biosciences Inc. (NASDAQ:XBIO) on Wednesday struck a definitive share exchange agreement to purchase Santersus AG, a privately held therapeutic medical device firm advancing its selective blood purification platform. The all-stock d…

Yahoo Finance Wed, 16 Sep 2026

Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

The combined company is expected to continue to trade on the Nasdaq Capital Market as Santersus Bio, Inc."The Proposed Transaction is expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on a single high-impac…

Yahoo Finance hu, 04 Jun 2026

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma

Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion Company reported strong positive preclinical results demonstrati…

Yahoo Finance Wed, 13 May 2026

Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform

Advancements across investigator-initiated studies, translational research and manufacturing activities supporting future clinical development Strengthened financial profile with continued royalty revenue growth Ended first quarter 2026 wit…

Yahoo Finance Wed, 22 Apr 2026

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

FRAMINGHAM, MA / ACCESS Newswire / April 22, 2026 /Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat …

XBIO — Frequently Asked Questions

What is the current share price of XBIO?

As of 2026-09-16 18:39 PDT, XBIO trades at $4.27 on NASDAQ/NYSE. Its 52-week range is $2.02 to $10.36.

What is the market capitalisation of XBIO?

XBIO has a market capitalisation of $9.79M on NASDAQ/NYSE.

What is the P/E ratio of XBIO?

XBIO trades at a trailing price-to-earnings (P/E) ratio of -2.70. Its price-to-book (P/B) ratio is 0.98.

What is the return on equity (ROE) of XBIO?

XBIO has a return on equity (ROE) of -36.25%. Its return on capital employed (ROCE) is -38.33%.

Is XBIO a good stock to buy?

This page provides a data-driven analysis of XBIO, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space